8-K: Allurion Announces Positive Topline Results From AUDACITY Trial

Allurion's AUDACITY trial demonstrates significant weight loss and a favorable safety profile for the Allurion Balloon at 48 weeks.

Summary

• Allurion Technologies announced positive topline results from its AUDACITY trial, which evaluated the safety and efficacy of the Allurion Balloon.
• The trial randomized 550 subjects to either two cycles of the Allurion Balloon or a control group receiving lifestyle therapy.
• The study measured co-primary endpoints at 48 weeks, approximately eight weeks after the second balloon passed.
• More than 50% of Allurion Balloon subjects lost more than 5% of their total body weight at 48 weeks (58%; p-value = 0.0089).
• Allurion Balloon subjects showed a 3.77% mean difference in total body weight loss compared to control subjects at 48 weeks, resulting in a 2.69% superiority margin.
• The 2.69% superiority margin was less than the pre-specified 3% margin needed to meet the comparative co-primary endpoint (p-value=0.1616).
• At 40 weeks, the mean difference in total body weight loss between groups was 4.22%, exceeding the 3% superiority margin.
• The rate of serious adverse events in Allurion Balloon subjects was 3.1%, the lowest reported in a pivotal FDA trial for a liquid-filled intragastric balloon.

Sentiment

Score: 7

Explanation: The document presents positive results regarding the efficacy and safety of the Allurion Balloon, but the failure to meet one of the co-primary endpoints and the need for FDA approval temper the overall sentiment.

Positives

• The AUDACITY trial demonstrated a greater than 50% responder rate for Allurion Balloon subjects.
• The Allurion Balloon showed substantially greater weight loss compared to the control group.
• The trial reported a low rate of serious adverse events, supporting a favorable safety profile.
• The results suggest the Allurion Balloon could be a valuable alternative to GLP-1 medications.
• The Allurion Balloon performed well without the customized digital platform that normally accompanies it commercially.

Negatives

• The 2.69% superiority margin at 48 weeks was less than the pre-specified 3% margin needed to meet the comparative co-primary endpoint.
• Higher-than-expected weight loss in control subjects impacted the comparative co-primary endpoint.

Risks

• The comparative co-primary endpoint was not met due to higher-than-expected weight loss in the control group.
• The Allurion Balloon is still an investigational device in the United States and requires FDA approval.
• The company faces risks related to obtaining and maintaining regulatory approvals and successfully commercializing its program.
• The company faces risks related to the evolution of the markets in which Allurion competes, including the impact of GLP-1s.
• The company faces risks related to the ability to defend its intellectual property.

Future Outlook

Allurion plans to submit the fourth and final module of the Pre-Market Approval (PMA) application to the FDA in 2025. Additional data on the AUDACITY trial will be presented at upcoming medical meetings.

Management Comments

• Dr. Shelby Sullivan stated that the results of the AUDACITY trial demonstrate a favorable benefit-risk profile for people with obesity.
• Dr. Ram Chuttani believes that the Allurion Balloon will be a novel and very useful therapy for people in the United States living with obesity.
• Dr. Shantanu Gaur was pleased with the performance of the Allurion Balloon subjects in the AUDACITY trial and looks forward to submitting the data to the FDA.

Industry Context

The results of the AUDACITY trial position the Allurion Balloon as a potential alternative to GLP-1 medications in the treatment of obesity, addressing a significant gap in the market.

Comparison to Industry Standards

• The AUDACITY trial is the first FDA pivotal trial on an intragastric balloon for weight loss to report primary outcomes beyond 9 months, setting a new benchmark for the industry.
• The 3.1% rate of serious adverse events is the lowest reported in a pivotal FDA trial for a liquid-filled intragastric balloon, indicating a superior safety profile compared to other similar devices.
• While the 2.69% superiority margin at 48 weeks did not meet the pre-specified 3% target, the 4.22% mean difference in total body weight loss at 40 weeks exceeded the 3% superiority margin, suggesting the Allurion Balloon is effective in the short term.
• Real-world experience outside the United States shows weight loss ranging from 14% to 22% when the Allurion Balloon is combined with the AI-powered Virtual Care Suite, exceeding the results observed in the AUDACITY trial, indicating the potential for even greater efficacy with the full Allurion program.

Stakeholder Impact

• Shareholders may react positively to the topline results, but the failure to meet one of the co-primary endpoints may temper enthusiasm.
• Patients may benefit from a new, less invasive weight loss option.
• Healthcare providers may be interested in offering the Allurion Balloon as a treatment option.

Next Steps

• Allurion plans to submit the fourth and final module of the Pre-Market Approval (PMA) application to the FDA in 2025.
• Additional data on the AUDACITY trial will be presented at upcoming medical meetings.

Key Dates

Keywords

Allurion Balloon, AUDACITY trial, weight loss, intragastric balloon, obesity treatment, FDA approval, clinical trial, safety profile, PMA submission, GLP-1 medications